Navigation Links
China Sky One Medical Completes Previously Announced Amendment to 2006 Form 10KSB
Date:11/8/2007

HARBIN, China, Nov. 8 /Xinhua-PRNewswire-FirstCall/ -- China Sky One Medical, Inc. (OTC Bulletin Board: CSKI), a manufacturer, marketer and distributor of pharmaceutical, medicinal and diagnostic products in China, today announced that it has completed the previously announced amendment to the Company's Form 10KSB for the year 2006. In working with new auditors and in completing the Form 10QSB for the three, six and nine month periods ended September 30, 2007, management determined that certain items were accounted for improperly in the year 2006.

Today's amendment does not impact financial results reported in the year 2007.

The restatement necessitates that net income for the year 2006 be adjusted to account for $3.67 million of costs that were incorrectly treated, including roughly $1.8 million of one-time costs related to the Company's 2006 recapitalization, as well as approximately $1.8 million of capitalized research and development costs which should have been charged to operations when incurred. As such, full year 2006 net income has been adjusted to $630,000 from $4.3 million.

About China Sky One Medical, Inc.

China Sky One Medical, Inc., a Nevada corporation, is a holding company whose principal operations are through its subsidiaries, which are engaged in the manufacturing, marketing and distribution of pharmaceutical, medicinal and diagnostic kit products. Through its wholly-owned subsidiaries, Harbin Tian Di Ren Medical Science and Technology Company ("TDR") and Harbin First Bio- Engineering Company Limited ("First"), the Company's principal revenue source is the manufacture and sale of over-the- counter pharmaceutical products. http://www.skyonemedical.com.

Safe Harbor Statement

Certain of the statements made in the press release constitute forward- looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statem
'/>"/>

SOURCE China Sky One Medical, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. Chinas 1-child policy could backfire on its elderly
2. Omnicom Acquires Leading Healthcare Marketing Communications Firm in China
3. Expanding Prevalent Population Will Drive Dramatic Growth for the Asthma Drug Market in China
4. Bridgetech Announces Addition of the Agency for Healthcare Research and Quality as Content Provider in its Development of a Healthcare Web Portal in China
5. China Holdings Appoints Ronald Shon Chairman of Advisory Board to Its Wholly-Owned Subsidiary China Power, Inc.
6. China Bionanometer Industries Corporation Promotes New Cosmetics Product Line in China
7. China Shenghuo Pharmaceutical Holdings, Inc. Begins Full-Scale Launch of 12Ways(R) Chinese Herbal Skin Care Product Line
8. Statement by Mike Leavitt Secretary of Health and Human Services on the United States-China Bilateral Meetings on Food and Drug Safety
9. Supplier Assessments to Help Buyers Identify Reliable China Exporters
10. Study shows lead-based paint problem isnt isolated to China
11. Bracco Announces Initiative to Save Children in China at 2007 Annual Meeting of CGI
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2008)...y 21 /PRNewswire-FirstCall/ -- Aflac Incorporated,...presentation at the Sanford,C. Bernstein & Co., LL...nce,2008., President and Chief Financial Officer ...ted, and he is scheduled to make a presentation on...orated presentation, Mr.,Cloninger will discuss th...
(Date:5/21/2008)...d SILVER SPRING, Md., May 21 /PRNewswire-USNewswir... (ADAA),( http://www.adaa.org ) and The HealthCent... announced that ADAA will join,HealthCentral,s gro...and,health experts dedicated to helping people suf... advice and support they need to cope with the,con...
(Date:5/21/2008)...s 1st quarter profit, enhanced operations and new ...ELES, May 21 /PRNewswire-FirstCall/ -- InstaCare C...butor of at-home testing diagnostics,for the chron...eveloper of,patent-pending technologies for e-heal...s for the first quarter period-ended March 31, 200...
(Date:5/21/2008)... Adverse Events in TORCH Showed Frequency Highest ...ONTO and RESEARCH TRIANGLE PARK, N.C., May 21 /PRN...500/50 (fluticasone propionate and,salmeterol inha...er of,cardiovascular adverse events compared to ot...from the TOwards a Revolution in COPD Health,(TORC...
Breaking Medicine News(10 mins):Health News:Aflac Incorporated to Present at the Sanford C. Bernstein & Co., LLC Twenty-Fourth Annual Strategic Decisions Conference 2008 2Health News:The Anxiety Disorders Association of America and The HealthCentral Network Form Alliance to Develop New Online Resources for Anxiety Disorders 2Health News:The Anxiety Disorders Association of America and The HealthCentral Network Form Alliance to Develop New Online Resources for Anxiety Disorders 3Health News:InstaCare Corp. in Turnaround Reports 258% Revenues Increase in 1Q 2008 2Health News:InstaCare Corp. in Turnaround Reports 258% Revenues Increase in 1Q 2008 3Health News:InstaCare Corp. in Turnaround Reports 258% Revenues Increase in 1Q 2008 4Health News:InstaCare Corp. in Turnaround Reports 258% Revenues Increase in 1Q 2008 5Health News:Three-Year COPD Study Found No Increase in Cardiac Events With Advair(R) 500/50 2Health News:Three-Year COPD Study Found No Increase in Cardiac Events With Advair(R) 500/50 3
...f contagious skin infections, the threat of pandem...oap and Detergent Association (SDA) to issue its s...a “C-minus”, a downgrade from 2004, when the count...nt than ever that people understand that clean han...
...eptember issue of Mayo Clinic Proceedings says tha..., all intravascular devices (IVDs) have an inheren...dult patients. An IVD is any device that allows ac...ter is the most commonly used device. As many as 5...
...called enzymes catalyze specific biochemical react...mic fluctuations//protein conformation or structur...recent findings reveal that it is the "dynamic ene... specific pathway that reduces the number and dime...
...d on Monday at a local hospital in Tulungagung, Ea...Health Ministry officials confirmed yesterday.// R...information center told Reuters that the boy had c...ts confirmed that he died to H5N1 virus infection....
Other Medicine News:Health News:America’s Clean Hands Report Card - Can’t Rise Above ‘C’ L 2Health News:America’s Clean Hands Report Card - Can’t Rise Above ‘C’ L 3Health News:Infection Risk High With All IVDs 2Health News:"Dynamic Energy Landscape" of enzyme in Catalysis 2
(Date:5/21/2008)... HILDEN, Germany, May 21 /...V Test as Front-line,Screen, Long-term data from ...Cancer show that women screened only with a human ...o develop moderate to severe cervical disease over...onal cytology (the Pap,"smear"). The research foll...
(Date:5/20/2008)...Statistically Significant Reduction of IBS Pain an...Effect Observed, SAN DIEGO, May 20 /...results of a recent Phase 2b study of its oral kap...onstrated statistically significant,results in the...adoline,produced significant improvement in diarrh...
(Date:5/20/2008)... 94 Percent of Men Maintained Normal Testosteron...Treatment 92 Percent of Men Expressed Sat...- Indevus,Pharmaceuticals, ... NEBIDO(R),(testosterone undecanoate), an investig...he treatment of hypogonadism, was presented in a l...
(Date:5/20/2008)...ata on Newly-Approved Cimzia(R) Presented at Diges...swire/ -- UCB announced today that data,presented ...sustainable,efficacy and safety of Cimzia(R) (cert...ts with moderate to severe Crohn,s disease. Data a...y of responders and the remission,rate remained st...
Breaking Medicine Technology:Study Finds QIAGEN's HPV Test Offers Greater Long-term Protection From Cervical Disease Than the Pap 2Study Finds QIAGEN's HPV Test Offers Greater Long-term Protection From Cervical Disease Than the Pap 3Study Finds QIAGEN's HPV Test Offers Greater Long-term Protection From Cervical Disease Than the Pap 4Tioga Pharmaceuticals' Asimadoline Demonstrates Positive Results in a Phase 2b Clinical Trial for the Treatment of Irritable Bowel Syndrome 2Tioga Pharmaceuticals' Asimadoline Demonstrates Positive Results in a Phase 2b Clinical Trial for the Treatment of Irritable Bowel Syndrome 3Tioga Pharmaceuticals' Asimadoline Demonstrates Positive Results in a Phase 2b Clinical Trial for the Treatment of Irritable Bowel Syndrome 4Indevus Presents Successful Phase III NEBIDO(R) Data at American Urological Association 2Indevus Presents Successful Phase III NEBIDO(R) Data at American Urological Association 3Indevus Presents Successful Phase III NEBIDO(R) Data at American Urological Association 4Cimzia(R) Provides Long-Term Efficacy with Stable Dosing in Crohn's Disease 2Cimzia(R) Provides Long-Term Efficacy with Stable Dosing in Crohn's Disease 3Cimzia(R) Provides Long-Term Efficacy with Stable Dosing in Crohn's Disease 4Cimzia(R) Provides Long-Term Efficacy with Stable Dosing in Crohn's Disease 5Cimzia(R) Provides Long-Term Efficacy with Stable Dosing in Crohn's Disease 6Cimzia(R) Provides Long-Term Efficacy with Stable Dosing in Crohn's Disease 7Cimzia(R) Provides Long-Term Efficacy with Stable Dosing in Crohn's Disease 8BLU MED Announces New Medical Preparedness Contracts 7283 1BLU MED Announces New Medical Preparedness Contracts 7283 2BioSpace Launches 2nd Edition of Southern Pharm 28TM 29 Hotbed Campaign 2027 1BioSpace Launches 2nd Edition of Southern Pharm 28TM 29 Hotbed Campaign 2027 2U S Patent 7 299 083 Awarded to Signalife 2023 1U S Patent 7 299 083 Awarded to Signalife 2023 2FDA Approves Cymbalta 28R 29 for Maintenance Treatment of Major Depressive Disorder 953 1FDA Approves Cymbalta 28R 29 for Maintenance Treatment of Major Depressive Disorder 953 2FDA Approves Cymbalta 28R 29 for Maintenance Treatment of Major Depressive Disorder 953 3FDA Approves Cymbalta 28R 29 for Maintenance Treatment of Major Depressive Disorder 953 4
...uture Pandemics , ,BETHESDA, Md., April 2, 2007--O...anish influenza pandemic is why it struck differen...cipalities such as,St. Louis spared the fate of th...emented similar public health measures? What made ...es funded by the,National Institutes of Health (NI...
...ent Therapy Significantly,Improved Absorption of F...y and DAYTON, Ohio, April 04, 2007 /PRNewswire/ --..., today unveiled,data from two phase III clinical ... formerly EUR-1008, for the treatment of,Exocrine ...ug,Administration (FDA) granted fast track status ...
Other Medicine Technology:Rapid Response was Crucial to Containing the 1918 Flu Pandemic 2Rapid Response was Crucial to Containing the 1918 Flu Pandemic 3Rapid Response was Crucial to Containing the 1918 Flu Pandemic 4Rapid Response was Crucial to Containing the 1918 Flu Pandemic 5Eurand Announces Positive Phase III Clinical Study Results 2Eurand Announces Positive Phase III Clinical Study Results 3Eurand Announces Positive Phase III Clinical Study Results 4Eurand Announces Positive Phase III Clinical Study Results 5
The Guidant INSIGNIA Ultra pacing system offers sophisticated patient-specific, easy-to-use features for simplified patient management and enhanced patient safety.
The 5500s electronic architecture incorporates advanced circuit designs optimized for efficiency and function. We call it HI VUE an engineering philosophy that directs the development of each subsys
The HI VISION 6500 high resolution digital ultrasound system offers advanced clinical imaging, enhanced operating efficiency, and remarkable clinical flexibility, all in robust and versatile configur
...features of the ELECTRA 1400C are designed to achi...away capabilities. This system includes automated ...nogen and factor assays in a single setup. It also...eparation of reference curves and patient sample d...
Medicine Products: